Genmab announced a pharma deal with Eli Lilly and Company to use and evaluate Genmab’s DuoBody technology platform for the creation of bispecific antibodies.

Lilly will initially evaluate the DuoBody technology platform in house.

The financial terms of the agreement have not been disclosed.

This agreement will not have a material impact on Genmab’s financial results and cash position.

View the full article at Genmab website.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Eli Lilly

Report: Antibody Partnering Terms and Agreements

Report: Partnering Deals and Alliances with Genmab

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter